Press release
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
- Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and
About this update from Incyte Corporation
[{"type":"text","content":"\n- Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms\n\n- Data featured as an oral presentation at the European Hidradenitis Suppurativa Foundation conference\n\n- Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory skin condition characterized by painful nodules and abscesses that can lead to irreversible tissue destruction and scarring1\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS). These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence, Italy.\n\nThe study previously met its primary endpoint, demonstrating that at Week 16 – the double-blind, placebo-controlled portion of the study – patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count versus placebo (least squares mean change, −2.5 [0.9], placebo vs. −5.2 [0.9], P=0.0277, povorcitinib 15 mg; −6.9 [0.9], P=0.0006, povorcitinib 45 mg; −6.3 [0.9], P=0.0021), povorcitinib 75 mg)2.\n\nNew results at Week 52, which include the 36-week open-label extension period during which all patients received povorcitinib 75 mg once daily (QD), show that average efficacy was sustained for all treatment arms following the switch to povorcitinib 75 mg QD (mean change in AN count from Day 1 baseline at Week 52 was −5.7 [7.3], placebo→75 mg; −8.4 [5.6], 15→75 mg; −10.4 [14.6], 45→75 mg; and −5.4 [5.6], 75 mg). Importantly, povorcitinib also demonstrated durable efficacy at Week 52 in high-threshold outcomes, as evidenced by 22-29% of patients achieving HS Clinical Response 100 (HiSCR100), which is defined as a 100% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.\n\nPovorcitinib was generally well tolerated and the safety profile was consistent with previously-reported data. The most common treatment-emergent adverse events (TEAEs) at Week ...